[财迷]-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

yong168
2022-10-27

[财迷]

大涨638%！LogicBio(LOGC.US)与阿斯利康子公司达成收购协议

智通财经APP获悉，10月3日，阿斯利康罕见病业务子公司Alexion宣布，已与Lexington公司(LOGC.US)达成最终收购协议。此次收购计划旨在通过LogicBio的独特技术、经验丰富的罕见病研发团队以及临床前开发方面的专业知识，快速加速Alexion在基因组药物领域的增长。受此消息影响，周一Lexington(LOGC.US)股价大涨637.61%。根据协议条款，Alexion将通过子公司发起现金收购要约，以每股2.07美元的价格收购LogicBio的所有流通股。双方董事会一致批准了该交易。Alexion计划在4到6周内完成交易，LogicBio员工将保留在当前职位。

大涨638%！LogicBio(LOGC.US)与阿斯利康子公司达成收购协议

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9986308198,"tweetId":"9986308198","gmtCreate":1666882143814,"gmtModify":1676537823675,"author":{"id":3570966674623757,"authorId":3570966674623757,"authorIdStr":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p><span>[财迷]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p><span>[财迷]&nbsp;</span></p></body></html>","text":"[财迷]","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9986308198","repostId":2272889814,"repostType":2,"repost":{"id":"2272889814","pubTimestamp":1664843762,"share":"https://www.laohu8.com/m/news/2272889814?lang=&edition=full","pubTime":"2022-10-04 08:36","market":"us","language":"zh","title":"大涨638%！LogicBio(LOGC.US)与阿斯利康子公司达成收购协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2272889814","media":"智通财经","summary":"智通财经APP获悉，10月3日，阿斯利康罕见病业务子公司Alexion宣布，已与Lexington公司(LOGC.US)达成最终收购协议。此次收购计划旨在通过LogicBio的独特技术、经验丰富的罕见病研发团队以及临床前开发方面的专业知识，快速加速Alexion在基因组药物领域的增长。受此消息影响，周一Lexington(LOGC.US)股价大涨637.61%。根据协议条款，Alexion将通过子公司发起现金收购要约，以每股2.07美元的价格收购LogicBio的所有流通股。双方董事会一致批准了该交易。Alexion计划在4到6周内完成交易，LogicBio员工将保留在当前职位。","content":"<html><body><p>智通财经APP获悉，10月3日，<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>罕见病业务子公司Alexion宣布，已与Lexington公司(LOGC.US)达成最终收购协议。此次收购计划旨在通过LogicBio的独特技术、经验丰富的罕见病研发团队以及临床前开发方面的专业知识，快速加速Alexion在基因组药物领域的增长。受此消息影响，周一Lexington(LOGC.US)股价大涨637.61%。</p><p><img src=\"https://img.zhitongcaijing.com/image/20221004/1664843856700190.png?x-oss-process=image/format,jpg/quality,Q_90\" title=\"1664843856700190.png\"/></p><p>根据协议条款，Alexion将通过子公司发起现金收购要约，以每股2.07美元的价格收购LogicBio的所有流通股。双方董事会一致批准了该交易。Alexion计划在4到6周内完成交易，LogicBio员工将保留在当前职位。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>大涨638%！LogicBio(LOGC.US)与阿斯利康子公司达成收购协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n大涨638%！LogicBio(LOGC.US)与阿斯利康子公司达成收购协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-04 08:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/801488.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，10月3日，阿斯利康罕见病业务子公司Alexion宣布，已与Lexington公司(LOGC.US)达成最终收购协议。此次收购计划旨在通过LogicBio的独特技术、经验丰富的罕见病研发团队以及临床前开发方面的专业知识，快速加速Alexion在基因组药物领域的增长。受此消息影响，周一Lexington(LOGC.US)股价大涨637.61%。根据协议条款，Alexion将通过...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/801488.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LOGC":"Logicbio Therapeutics Inc.","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4007":"制药","AZN":"阿斯利康"},"source_url":"http://www.zhitongcaijing.com/content/detail/801488.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2272889814","content_text":"智通财经APP获悉，10月3日，阿斯利康罕见病业务子公司Alexion宣布，已与Lexington公司(LOGC.US)达成最终收购协议。此次收购计划旨在通过LogicBio的独特技术、经验丰富的罕见病研发团队以及临床前开发方面的专业知识，快速加速Alexion在基因组药物领域的增长。受此消息影响，周一Lexington(LOGC.US)股价大涨637.61%。根据协议条款，Alexion将通过子公司发起现金收购要约，以每股2.07美元的价格收购LogicBio的所有流通股。双方董事会一致批准了该交易。Alexion计划在4到6周内完成交易，LogicBio员工将保留在当前职位。","news_type":1},"isVote":1,"tweetType":1,"viewCount":156,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}